Treating CRS and ICANS: current approaches and future outlooks

(2:9)

Managing and treating CRS, neurological toxicity and cytopenias associated with CAR-T therapy

(2:6)

Strategies to minimize the occurrence of CRS and ICANS in patients treated with CAR-T therapy

(1:31)

Treatment options for severe and refractory CRS

(4:26)

Ask The Expert CSR

(4:36)

CAR-T Toxicities: CRS and ICANS

(30:53)

Managing the adverse events associated with epcoritamab treatment: focus on CRS

(1:50)

What is cytokine release syndrome? #myeloma

(11:42)

What are the management strategies for CRS and ICANS in MM?

(6:49)

Dealing with the issue of sepsis vs. CRS in CAR-T patients

(1:6)

Cytoreductive Surgery + HIPEC: What is it?

(9:51)

CAR T-cell Therapy for Pediatric Cancer | Satiro de Oliveira, MD | UCLAMDChat

(31:47)

What is Cytokine Release Syndrome or CRS?

(1:14)

CAR T-cell toxicity: CRS, ICANS and prolonged cytopenias

(3:43)

“Treating Peritoneal Cancers with CRS + HIPEC” | Full Webinar + Q\u0026A | HipecTreatment.com

(25:46)

Immunological Approaches: CARS to armored CARS - T cell treatment of cancer

(24:31)

Siltuximab for first-line treatment of CRS in patients receiving CAR-T therapy

(2:42)

AbScent Presents: EPOS 4 Patients - how patients shaped CRS treatment guidelines

(50:42)

Current treatment strategies for CRS and insights into other CAR-related toxicities

(1:51)

Management of cytokine release syndrome and neurotoxicity: an emerging need

(2:15)